C
1.31
-0.01 (-0.76%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Bullish |
| Biotechnology (Global) | Bullish | Bullish | |
| Stock | Clearside Biomedical, Inc. | Bearish | - |
|
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Carmignac Gestion | 31 Dec 2023 | 2,132,744 |
| Brown Wealth Management, Llc | 31 Dec 2023 | 110,000 |
| Synovus Financial Corp | 31 Dec 2023 | 53,071 |
| 52 Weeks Range |
0.650 - 2.12
|
|
| Price Target Range | ||
| High | 6.00 (HC Wainwright & Co., 358.02%) | Buy |
| Median | 4.50 (243.51%) | |
| Low | 4.00 (Needham, 205.34%) | Buy |
| 4.00 (Wedbush, 205.34%) | Outperform | |
| Average | 4.75 (262.60%) | |
| Total | 2 Buy, 1 Outperform, 1 Market Outperform | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 11 Apr 2024 | 4.00 (205.34%) | Buy | 1.30 |
| 13 Mar 2024 | 4.00 (205.34%) | Buy | 1.63 | |
| HC Wainwright & Co. | 14 Mar 2024 | 6.00 (358.02%) | Buy | 1.73 |
| JMP Securities | 13 Mar 2024 | 5.00 (281.68%) | Market Outperform | 1.63 |
| Wedbush | 13 Mar 2024 | 4.00 (205.34%) | Outperform | 1.63 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Apr 2024 | Announcement | Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024 |
| 16 Apr 2024 | Announcement | Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors |
| 02 Apr 2024 | Announcement | Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference |
| 18 Mar 2024 | Announcement | Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer |
| 12 Mar 2024 | Announcement | Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update |
| 29 Feb 2024 | Announcement | Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024 |
| 07 Feb 2024 | Announcement | Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |